

## Drug and Therapeutics Committee – Minutes

<b>Date / Time</b>	December 9 <sup>th</sup> 2021 8.15-9.30
<b>Venue</b>	Microsoft Teams
<b>Chair</b>	Prof A Morice, Chair, Professor of Respiratory Medicine
<b>Notes / Action Points</b>	Jane Morgan – Principal Pharmacist
<b>Quorate: Yes / No</b>	Yes

<b>Attendance</b>	Prof M Lind, Vice Chair, Professor of Oncology, HUTH Mr K McCorry, Medicines Optimisation Pharmacist, NECS Miss J Morgan, Professional Secretary, Principal Pharmacist – Formulary HUTH Dr O Ogunbambi, Consultant Rheumatologist, HUTH Ms J Goode, Chief Pharmacist, HUTH Mr P O'Brien, Deputy Chief Pharmacist, HUTH Mr R Kapur, Consultant Vascular Surgeon, HUTH Dr S Raise, GP Prescribing Lead, ER CCG Dr B Ali, GP Prescribing Lead, Hull CCG Dr A Samson, Consultant Infectious Diseases, HUTH
-------------------	---

<b>Apologies</b>	Dr H Klonin, Consultant Paediatrician, HUTH Prof T Sathyapalan, Consultant Endocrinologist, HUTH
------------------	---

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
2021.12.01	<b>Apologies</b>	As Above.					
2021.12.02	<b>Declarations of Interest</b>						
2021.12.03	<b>Minutes of the previous meeting</b>	Accepted as an accurate record	no action required				12/21
2021.12.04	<b>Action Tracker</b>	<p><b>Dissemination of Information Across All Healthcare Groups /Providers</b> Extended for 6 months.</p> <p><b>Clinical Guidelines – Biologics and Small molecules in Inflammatory</b> JM to request update of ustekinumab report prior to January meeting AM requested updated guideline – action complete</p> <p><b>Hydroxychloroquine in RA</b> – JM to send Harrogate/West Yorkshire guidance to OO and Mr Vize</p> <p><b>Clinical guidelines – Tolvaptan</b> Action complete</p> <p><b>New product requests</b> AM written to applicant JM updated formulary</p> <p><b>New product requests – Dienogest</b> JM requested pathway and will have ready for HERPC</p> <p><b>Aria forms – Zoledronic acid</b> JM checked with Dr Aye and no trust guidance. To author one from pharmacy in conjunction with DME pharmacy team.</p> <p><b>NICE TA735 (Tofacitinib in JIA)</b> JM e-mailed NHSE awaiting response</p>	<p>To continue escalating and review in 6 months</p> <p>To request updated report for next meeting</p> <p>Action complete</p> <p>Ongoing</p> <p>Action complete</p> <p>Actions complete</p> <p>Action complete</p> <p>Ongoing</p> <p>Ongoing</p>	<p>Add to May agenda</p> <p>Add to Jan agenda</p> <p>No further action</p> <p>To send guidance</p> <p>No further action</p> <p>No further action</p> <p>No further action</p> <p>To write guideline</p> <p>To update next time</p>	<p>JM</p> <p>JM</p> <p>JM</p> <p>JM</p> <p>JM</p> <p>JM</p> <p>JM</p> <p>JM</p>	<p>5/22</p> <p>1/22</p> <p>12/22</p> <p>5/22</p> <p>12/21</p>	<p>12/21</p> <p>12/21</p> <p>12/21</p> <p>12/21</p>

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		<p><b>NICE TA 738 (Berotralstat)</b> JM requested application from Dr Gordins</p> <p><b>NICE TA734 (Secukinumab)</b> Dr Zaman confirmed she would like to use this TA. Biologics pharmacist been to see Dr Zaman and updating psoriasis and Psoriatic arthritis pathway for HERPC</p> <p><b>MHRA Drug Safety Update – Tofacitinib</b> Biologics pharmacist run report and informing relevant clinicians of patients who received tofacitinib</p> <p><b>MHRA Drug Safety Update – Chloral Hydrate</b> JM informed Advanced Clinical Pharmacist for paediatrics who will discuss at paediatric governance. Consultant paediatrician with interest in neurology contacted pharmacy following statement from BPNA to help with identifying patients for review.</p> <p><b>Clinical Guidelines – Phenytoin</b> JM informed author and added to CEPPDC agenda</p> <p><b>Clinical Guidelines – Opioid induced constipation</b> JM informed author</p>	<p>Ongoing</p> <p>Action complete</p> <p>Action complete</p> <p>Action complete</p> <p>Action complete</p> <p>Action complete</p>	<p>To update next time</p> <p>No further action</p> <p>No further action</p> <p>No further action</p> <p>No further action</p> <p>No further action</p>	<p>JM</p> <p>JM</p> <p>JM</p> <p>JM</p> <p>JM</p> <p>JM</p>	<p>1/22</p> <p></p> <p></p> <p></p> <p></p> <p></p>	<p></p> <p>12/21</p> <p>12/21</p> <p>12/21</p> <p>12/21</p> <p>12/21</p>
2021.12.05	<b>New Product Requests</b>	<p><b>New Product Requests</b> <u>Upadacitinib (atopic dermatitis) – Dr Zaman</u> JM summarised the evidence for this product that has 2 NICE TAs for its other indication. The RMOc free of charge scheme was discussed and it was noted that a number of other products including baricitinib and dupilumab have TAs for atopic dermatitis so it does not fulfil the requirement for unmet clinical need. However, it was acknowledged that a small number of patients might have tried and failed other treatment. Rejected for addition to formulary. Available for chairs approvals only.</p>	<p>Rejected for inclusion on formulary. Available for chairs approval</p>	<p>AM to write to applicants</p> <p>JM to update formulary</p>	<p>AM</p> <p>JM</p>	<p>1/22</p> <p>1/22</p>	

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		<p><u>Tebentafusp – Dr Ranatunge</u> JM summarised the limited evidence from one study. There are no NICE approved therapies for metastatic uveal melanoma; so is an unmet clinical need. Treatment used is for metastatic melanoma and is not very effective for metastatic uveal melanoma. ML highlighted lack of availability of effective treatments and risk that clinicians will use treatments with even less evidence. This is available free of charge from manufacturer until NICE/CDF issue guidance.</p> <p><b>Line Extension</b></p> <ul style="list-style-type: none"> <li>Accrete D3 once a day</li> </ul> <p>JM discussed the calcium and vitamin D products stocked in HUTH pharmacy as multiple preparations are stocked to enable a wide range of patient choice. JM to remove Calcichew D3 forte from formulary and add Accrete D3 in place. KMc raised risk of using Accrete D3 daily as twice a day product. SR asked about Evacal D3 that is preferred brand in primary care; POB to check contracts to see if can use Evacal D3 instead of Adcal D3.</p> <p><b>Aria</b> TA740/TA741 – Apalutamide - approved</p>	<p>Approved</p> <p>Accrete D3 once a day approved. Calcichew D3 forte to be removed from formulary.</p>				
2021.12.06	<b>NICE guidance – November</b>	<p><b>Nice Guidance</b></p> <ul style="list-style-type: none"> <li>NG191 <a href="#">COVID-19 rapid guideline: managing COVID-19</a></li> <li>CG187 <a href="#">Acute heart failure: diagnosis and management</a></li> <li>TA746 <a href="#">Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer</a> On formulary for other TAs</li> <li>TA747 <a href="#">Nintedanib for treating progressive fibrosing interstitial lung diseases</a> On formulary for other TAs</li> </ul>	<p>Noted</p> <p>Noted</p> <p>Noted</p> <p>Noted</p>	<p>No further action</p> <p>No further action</p> <p>No further action</p> <p>No further action</p>			

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		<ul style="list-style-type: none"> <li>NG208 <a href="#">Heart valve disease presenting in adults: investigation and management</a></li> <li>NG188 <a href="#">COVID-19 rapid guideline: managing the long-term effects of COVID-19</a></li> <li>TA744 <a href="#">Upadacitinib for treating moderate rheumatoid arthritis</a> On formulary for other TAs. OO confirmed rheumatology would use this TA</li> <li>TA745 <a href="#">NBTXR-3 for treating advanced soft tissue sarcoma (terminated appraisal)</a></li> <li>NG207 <a href="#">Inducing labour</a> Misoprostol 25 microgram recommended JM to discuss with family and women's lead pharmacist</li> <li>TA742 <a href="#">Selpercatinib for treating advanced thyroid cancer with RET alterations</a> Previous application received to add to formulary for this TA and inform applicant</li> <li>TA743 <a href="#">Crizanlizumab for preventing sickle cell crises in sickle cell disease</a> JM to confirm if HUTH commissioned</li> <li>NG28 Type 2 diabetes in adults: management</li> <li>HST16 <a href="#">Givosiran for treating acute hepatic porphyria</a> JM to confirm if HUTH commissioned</li> <li>NG203 <a href="#">Chronic kidney disease: assessment and management</a></li> <li>NG126 <a href="#">Ectopic pregnancy and miscarriage: diagnosis and initial management</a> New info on micronized progesterone in miscarriage. JM to check if products already stocked are appropriate</li> <li>NG143 <a href="#">Fever in under 5s: assessment and initial management</a></li> </ul>	<p>Noted</p> <p>Noted</p> <p>Noted</p> <p>Terminated appraisal</p> <p>To add to formulary and review unlicensed list Application approved</p> <p>Confirm if HUTH commissioned</p> <p>Noted</p> <p>Confirm if HUTH commissioned</p> <p>Noted</p> <p>Check products</p> <p>Noted</p>	<p>No further action</p> <p>No further action</p> <p>No further action</p> <p>No further action</p> <p>JM to discuss with FWH pharmacist</p> <p>JM update formulary and inform applicant</p> <p>Update formulary and check NHSE commissioning</p> <p>No further action</p> <p>Update formulary and check</p> <p>No further action</p> <p>JM to check licensed products and discuss with F&amp;WH pharmacist</p> <p>No further action</p> <p>No further action</p>	<p></p> <p></p> <p></p> <p>JM</p> <p>JM</p> <p>JM</p> <p>JM</p> <p></p> <p>JM</p> <p></p> <p>JM</p> <p></p>	<p></p> <p></p> <p></p> <p>1/22</p> <p>1/22</p> <p>1/22</p> <p>1/22</p> <p></p> <p>1/22</p> <p></p> <p>1/22</p> <p></p>	

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		<ul style="list-style-type: none"> <li>NG209 <a href="#">Tobacco: preventing uptake, promoting quitting and treating dependence</a></li> <li>MTG61 <a href="#">Synergo for non-muscle-invasive bladder cancer</a></li> </ul>	Noted  Noted	No further action			
2021.12.07	<b>MHRA Drug safety update – November 2021</b>	Contents noted	Complete	No action required			12/21
2021.12.08	<b>Minutes of the Safe Medication Practice Committee</b> September 2021	Contents noted	Complete	No action required			12/21
2021.12.09	<b>Minutes from the Hull and East Riding Prescribing Committee</b> September 2021	Contents noted	Complete	No action required			12/21
2021.12.10	<b>Regional Medicines Optimisation Committee</b>	Nil this month					
2021.12.11	<b>Clinical guidelines</b>	<ul style="list-style-type: none"> <li>Sarilumab guideline (update) JM presented update to guidance and POB updated on stock situation for both sarilumab and tocilizumab</li> <li>Ronapreve® guideline (update) JM presented update to this guidance which had a new indication added.</li> </ul>	Approved  Approved	JM to arrange upload onto Pattie  JM to arrange upload onto Pattie	JM  JM	1/22  1/22	
2021.12.12	<b>Correspondence received</b>	Nil					
2021.12.13	<b>Chairs Approvals</b>	<ul style="list-style-type: none"> <li>Bevicizumab HHT bleeding from AVM in finger - Prof Morice – approval by Prof Lind</li> <li>Tebentafusp for ciliary body melanoma – Dr Ranatunge</li> </ul>	Complete	No action required			
2021.12.14	<b>Issues to escalate to</b>	Nil to escalate	Complete	No action required			

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
	PE&CE						
2021.12.15	Any Other Business	POB raised the RCGP/BMA communication to NICE regarding inclisiran NICE TA and NHSE guidance regarding initiation in primary care. Local draft pathway recommends lipid clinic	HERPC to review pathway from Lipid clinic.	JM to add to HERPC agenda	JM	1/22	
2021.12.16	Date and Time of Next Meeting	13 <sup>th</sup> Jan 2022					